Delivery Order SPE2DB22D1106-SPE2DB25FFHZ5
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $46,942.37 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $3,418.92 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 20, 2025, and is being performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $13,364.64 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injections on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price, non-competitive delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $17,361.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen auto-injectors on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price contract represents a competitively awarded delivery order with no set-aside designation, supporting federal medical procurement needs for military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHZ5Delivery Order
The Defense Logistics Agency awarded a $39,157.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL pen injections on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was made on a non-set-aside, competitive basis and will be performed at the contractor's Corporate Office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems through the DLA Medical Supply Chain. The company's portfolio encompasses a broad range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. This delivery order continues the contractor's essential role in supplying specialty pharmaceutical products to support Defense Health Agency operations and other federal healthcare customers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $39.2k | 9/10/25 |